64 research outputs found
Search for Exotic Mesons in pi- P Interactions at 18 GeV/c
The recent search for non mesons in interactions at
Brookhaven National Laboratory is summarized. Many final states such as , , , , , ,
which are favored decay modes of exotics, are under investigation.Comment: 9 pages, PostScript, Presented at the International School of Nuclear
Physics, Erice, Sicily, Italy, September 199
Confirmation of a pi_1^0 Exotic Meson in the \eta \pi^0 System
The exclusive reaction , at 18 GeV has been studied with a partial wave analysis on a sample
of 23~492 events from BNL experiment E852. A mass-dependent fit
is consistent with a resonant hypothesis for the wave, thus providing
evidence for a neutral exotic meson with , a mass of MeV, and a width of MeV. New
interpretations of the meson exotics in neutral system observed in
E852 and Crystal Barrel experiments are discussed.Comment: p3, rewording the paragraph (at the bottom) about the phase
variations. p4, rewording paragrath "The second method ..." . p4, at the
bottom of paragrath "The third method ..." added consistent with the results
of methods 1 and 2
Observation of a New J(PC)=1(+-) Isoscalar State in the Reaction Pi- Proton -> Omega Eta Neutron at 18 GeV/c
Results are presented on a partial wave analysis of the Omega Eta final state
produced in Pi- Proton interactions at 18 GeVc where Omega -> Pi+ Pi- Pi0, Pi0
-> 2 Gammas, and Eta -> 2 Gammas. We observe the previously unreported decay
mode Omega(1650) -> Omega Eta and a new 1(+-) meson state h1(1595) with a mass
M=1594(15)(+10)(-60) MeV/c^2 and a width Gamma=384(60)(+70)(-100) MeV/c^2. The
h1(1595) state exhibits resonant-like phase motion relative to the Omega(1650).Comment: Submitted to Physics Letters B Eight total pages including 11 figures
and 1 tabl
A study of the reaction pim p --> omega pim p at 18 GeV/c: The D and S decay amplitudes for b1(1235) --> omega pi
The reaction pim p --> omega pim p, omega --> pip pim pi0 has been studied at
18 GeV/c. The omega pim mass spectrum is found to be dominated by the b1(1235).
Partial Wave Analysis shows that b1 production is dominated by natural parity
exchange. The S-wave and D-wave amplitudes for b1(1235) --> omega pi have been
determined, and it is found that the amplitude ratio, |D/S| = 0.269 +/-
(0.009)stat +/- (0.01)sys and the phase difference, phi(D-S) = 10.54 deg +/-
(2.4)stat +/- (3.9)sys.Comment: 7 pages, 9 figures, revtex4 format, to be published in Physics
Letters
Chromosome stickiness during meiotic behavior analysis of Passiflora serrato-digitata L. (PassifloraCEAE)
Preliminary antigenic characterisation of an adult worm vomit preparation of Fasciola hepatica by infected human sera
Traumatic bilateral internal carotid artery dissection following airbag deployment in a patient with fibromuscular dysplasia
Synergistic enhancement of beta-lactam antibiotics by modified tunicamycin analogs TunR1 and TunR2
The β-lactams are the most widely used group of antibiotics in human health and agriculture, but this is under threat due to the persistent rise of pathogenic resistance. Several compounds, including tunicamycin (TUN), can enhance the antibacterial activity of the β-lactams to the extent of overcoming resistance, but the mammalian toxicity of TUN has precluded its use in this role. Selective hydrogenation of TUN produces modified compounds (TunR1 and TunR2), which retain the enhancement of β-lactams while having much lower mammalian toxicity.
Here we show that TunR1 and TunR2 enhance the antibacterial activity of multiple β-lactam family members, including penems, cephems, and third-generation penicillins, to a similar extent as does the native TUN. Eleven of the β-lactams tested were enhanced from 2 to >256-fold against Bacillus subtilis, with comparable results against a penicillin G-resistant strain. The most significant enhancements were obtained with third-generation aminothiazolidyl cephems, including cefotaxime, ceftazidime, and cefquinome. These results support the potential of low toxicity tunicamycin analogs (TunR1 and TunR2) as clinically valid, synergistic enhancers for a broad group of β-lactam antibiotics
- …
